HP515

Phase 2Small molecule

HHinova Pharmaceuticals Inc.

HP515 is one of 14 small molecule programs targeting Alcoholic Fatty Liver Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alcoholic Fatty Liver DiseaseRecruiting

Alcoholic Fatty Liver DiseasePhase 2

Recruiting

Competition

Competitive Landscape

14 competitors in Alcoholic Fatty Liver Disease

#DrugCompanyPhaseTrials

Crestor

AstraZeneca

Approved

1 2

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

2 3

Micardis

Boehringer Ingelheim

Approved

1 4

Fosamax

Prolia

Tricor

2 7

Efruxifermin

Akero Therapeutics

Phase 3

1 8

Trulicity

Eli Lilly

Preclinical

1 9

Niacor

AbbVie

Preclinical

1 10

Invokana

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Alcoholic Fatty Liver Disease

NCT07308548

Clinical

Trials by Indication[1]

Alcoholic Fatty Liver Disease1 trial

A Trial to Evaluate the Efficacy, Safety, PK, and PD of HP515 in Non - Alcoholic Fatty Liver Disease ( NASH/MASH )

Recruiting·HHinova Pharmaceuticals Inc.·Phase 2·NCT07308548·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HP515. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HP515 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HP515. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hinova Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHinova Pharmaceuticals Inc.

HP515

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Alcoholic Fatty Liver Disease1 trial

References

Drug Info

Quick Facts

Related News